Transthyretin Amyloidosis Treatment Market
According to Intent Market Research, the Transthyretin Amyloidosis Treatment Market is expected to grow from USD 5.1 billion in 2024-e at a CAGR of 10.3% to touch USD 10.1 billion by 2030. The Transthyretin Amyloidosis Treatment Market is dominated by key players such as Alnylam Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, and Teva Pharmaceuticals.